Last reviewed · How we verify
ethinylestradiol and drospirenone
Ethinylestradiol and drospirenone is a marketed drug developed by Adana Numune Training and Research Hospital, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, though specific revenue figures and primary indication details are not provided. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | ethinylestradiol and drospirenone |
|---|---|
| Also known as | Yasmin; Bayer HealthCare Berlin, Germany |
| Sponsor | Adana Numune Training and Research Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Anxiety and Depression in Adolescent PCOS (NA)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants (PHASE1)
- Oral Contraceptive Pills Versus Levonorgestrel-Releasing Intrauterine System for Niche-Related Abnormal Uterine Bleeding (NA)
- A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies (PHASE1)
- Effect of Drospirenone-Ethinyl Estradiol (20microgram vs 30 Microgram) on Free Androgen Index in PCOS (NA)
- Efficacy of Oral Contraceptive, Progesterone, and Inositol on Menstrual Regulation in PCOS (NA)
- Continuous Versus Cyclical OCP Use in PCOS (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: